Salute e Benessere
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
"For too long, serious liver diseases like MASH have gone under the radar—but with MASH rates soaring alongside the global obesity epidemic, it's time to tackle liver disease head on," said Sandy Sommer, Head of the Therapeutic Area for Cardiovascular, Renal and Metabolic at Boehringer Ingelheim. "Obesity and MASH are deeply interconnected chronic diseases that no organization can tackle alone. At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to drive transformative change in metabolic health for patients, doctors, and healthcare systems worldwide."
MASH is a chronic disease that results from excess fat accumulation and inflammation in the liver. It is more common in people living with obesity and, left untreated, can lead to scarring, cirrhosis, and liver failure. Because the disease is often silent in its early stages, it is estimated that fewer than one in five people with MASH are formally diagnosed, underscoring the urgent need for scalable and non-invasive tools to screen these patients and support them with ongoing care.
FibroScan , Echosens' non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim's liver disease research and continues to support two ongoing Survodutide Phase III trials by screening and monitoring patients; as a non-invasive test, FibroScan offers a fast, painless, cost-effective, and scalable alternative to liver biopsy. Survodutide combines GLP-1 and glucagon receptor agonists as a novel potential treatment for MASH and associated metabolic conditions like obesity.
Survodutide is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal and metabolic disease areas. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally.
"We are excited to expand our collaboration with Boehringer Ingelheim, whose innovative approach has the potential to further advance the treatment landscape for MASH," said
Dominique Legros , CEO of Echosens. "This partnership reflects our ongoing commitment to support the global liver disease community by enabling smarter clinical trials and broader access to non-invasive diagnostic tools. We are proud to collaborate with Boehringer Ingelheim and welcome them into our shared mission to improve liver health outcomes."
Logo - https://mma.prnewswire.com/media/2370966/5336318/Logo_Logo.jpg
Photo - https://mma.prnewswire.com/media/2706760/Boehringer_Collab_Tile_Accent_Green.jpg
View original content:https://www.prnewswire.co.uk/news-releases/echosens-and-boehringer-ingelheim-expand-long-standing-collaboration-to-accelerate-progress-in-mash-diagnosis-and-care-302476791.html